Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deoxythymidine and Deoxycytidine for TK2 Deficiency
NCT03639701Phase 2Active, not recruiting
- Sponsor
- Columbia University
- Start
- May 2017
- Primary completion
- Dec 2026
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of doxribtimine, 2'-deoxycytidine in thymidine kinase 2 deficiency (TK2D), sponsored by Columbia University. Started May 2017; status: active, not recruiting.
02
Drugs
doxribtimine2'-deoxycytidine
03
Conditions
thymidine kinase 2 deficiency (TK2D)
Beyond the preview
Go deeper on NCT03639701.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03639701.